Darunavir (Prezista®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32014000508
English
Authors' recommendations:
Darunavir (Prezista®) is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus 1 (HIV 1) infection in paediatric patients from the age of 12 years and at least 40 kg body weight who are: antiretroviral therapy (ART)-naive; or ART-experienced with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10⁶/l. In deciding to initiate treatment with darunavir in such ART-experienced patients, genotypic testing should guide the use of darunavir.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/2246
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Sulfonamides
- HIV Protease Inhibitors
- HIV Infections
- Child
- Adolescent
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.